Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: Comparison to conventional antiretrovirals

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3056-3064

  De Campos, Walter Rangel Lopes ^a   Coopusamy, Dayaneethie ^a   Morris, Lynn ^b   Mayosi, Bongani M ^c   Khati, Makobetsa ^a  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPRENAVIR; ANTIRETROVIRUS AGENT; APTAMER; B40 APTAMER; CASPASE 3; CASPASE 7; CELL NUCLEUS DNA; CYTOCHROME P450 3A4; DARUNAVIR; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN GP 120; INDINAVIR; LAMIVUDINE; LOPINAVIR; MITOCHONDRIAL DNA; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CELL DEATH; CELL VIABILITY; CLADISTICS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; HEART CELL CULTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL TOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; VIRUS ENTRY;

ANTI-HIV AGENTS; APTAMERS, NUCLEOTIDE; CASPASE 3; CASPASE 7; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DNA, MITOCHONDRIAL; DNA, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; MONOAMINE OXIDASE; MYOCYTES, CARDIAC; POLYMERASE CHAIN REACTION; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 67649960147     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01502-08     Document Type: Article

References (71)

1. Baba, M., M. Okamoto, M. Makino, Y. Kimura, T. Ikeuchi, T. Sakaguchi, and T. Okamoto. 1997. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1250-1255.
2. Badley, A. D. 2005. In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ. 12(Suppl. 1):924-931.
3. Beck, E. J., M. Vitoria, S. Mandalia, S. Crowley, C. F. Gilks, and Y. Souteyrand. 2006. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 20:1497-1502.
4. Bongiovanni, M., P. Cicconi, S. Landonio, P. Meraviglia, L. Testa, A. Di Biagio, E. Chiesa, F. Tordato, T. Bini, and A. Monforte. 2005. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int. J. Antimicrob. Agents 26:88-91.
5. Braestrup, C., H. Andersen, and A. Randrup. 1975. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmacol. 34:181-187.
6. Brinkman, K. 2001. Evidence for mitochondrial toxicity: lactic acidosis as proof of concept. J. HIV Ther. 6:13-16.
7. Brinkman, K., and T. N. Kakuda. 2000. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr. Opin. Infect. Dis. 13:5-11.
8. Brinkman, K., J. A. Smeitink, J. A. Romijn, and P. Reiss. 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:1112-1115.
9. Carr, A., and D. A. Cooper. 2000. Adverse effects of antiretroviral therapy. Lancet 356:1423-1430.
10. Carr, A., J. Miller, M. Law, and D. A. Cooper. 2000. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14:F25-F32.
11. Carr, A., K. Samaras, S. Burton, M. Law, J. Freund, D. J. Chisholm, and D. A. Cooper. 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58.
12. Carr, A., K. Samaras, D. J. Chisholm, and D. A. Cooper. 1998. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351:1881-1883.
13. Carrillo, A., K. D. Stewart, H. L. Sham, D. W. Norbeck, W. E. Kohlbrenner, J. M. Leonard, D. J. Kempf, and A. Molla. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:7532-7541.
14. Chowdhury, I., B. Tharakan, and G. K. Bhat. 2008. Caspases - an update. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 151:10-27.
15. Chu, C. K., R. F. Schinazi, B. H. Arnold, D. L. Cannon, B. Doboszewski, V. B. Bhadti, and Z. P. Gu. 1988. Comparative activity of 2′,3′-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. Biochem. Pharmacol. 37:3543-3548.
16. Coates, J. A., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
17. Cohen, C., M. Forzan, B. Sproat, R. Pantophlet, I. McGowan, D. Burton, and W. James. 2008. An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 381:46-54.
18. Dams, R., T. H. Benijts, W. E. Lambert, J. F. Van Bocxlaer, D. Van Varenbergh, C. Van Peteghem, and A. P. De Leenheer. 2001. A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J. Anal. Toxicol. 25:147-151.
19. De Meyer, S., H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, R. Pauwels, P. Wigerinck, and M. P. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitorresistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
20. Dey, A. K., C. Griffiths, S. M. Lea, and W. James. 2005. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 11:873-884.
21. Dey, A. K., M. Khati, M. Tang, R. Wyatt, S. M. Lea, and W. James. 2005. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol. 79:13806-13810.
22. DiMauro, S., and E. A. Schon. 2003. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348:2656-2668.
23. Drolet, D. W., J. Nelson, C. E. Tucker, P. M. Zack, K. Nixon, R. Bolin, M. B. Judkins, J. A. Farmer, J. L. Wolf, S. C. Gill, and R. A. Bendele. 2000. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17:1503-1510.
24. Edmondson, D. E., A. Mattevi, C. Binda, M. Li, and F. Hubalek. 2004. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 11: 1983-1993.
25. Elbekai, R. H., and A. O. El-Kadi. 2006. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol. Ther. 112:564-587.
26. Elsworth, J. D., V. Glover, G. P. Reynolds, M. Sandler, A. J. Lees, P. Phuapradit, K. M. Shaw, G. M. Stern, and P. Kumar. 1978. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect.' Psychopharmacology (Berlin) 57:33-38.
27. Ernest, C. S., II, S. D. Hall, and D. R. Jones. 2005. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 312:583-591.
28. Eyetech Study Group. 2003. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110:979-986.
29. Eyetech Study Group. 2002. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143-152.
30. Gaedicke, S., E. Firat-Geier, O. Constantiniu, M. Lucchiari-Hartz, M. Freudenberg, C. Galanos, and G. Niedermann. 2002. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res. 62:6901-6908.
31. Gragoudas, E. S., A. P. Adamis, E. T. Cunningham, Jr., M. Feinsod, and D. R. Guyer. 2004. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351:2805-2816.
32. Grimsby, J., N. C. Lan, R. Neve, K. Chen, and J. C. Shih. 1990. Tissue distribution of human monoamine oxidase A and B mRNA. J. Neurochem. 55:1166-1169.
33. Guengerich, F. P. 2001. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14:611-650.
34. Herskowitz, A., S. B. Willoughby, K. L. Baughman, S. P. Schulman, and J. D. Bartlett. 1992. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann. Intern. Med. 116:311-313.
35. Hewton, R., A. Salem, and R. J. Irvine. 2007. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor. Clin. Exp. Pharmacol. Physiol. 34:1051-1057.
36. Ikezoe, T., Y. Hisatake, T. Takeuchi, Y. Ohtsuki, Y. Yang, J. W. Said, H. Taguchi, and H. P. Koeffler. 2004. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 64:7426-7431.
37. Kakuda, T. N. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22:685-708.
38. Kakuda, T. N., R. C. Brundage, P. L. Anderson, and C. V. Fletcher. 1999. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 13:2311-2312.
39. Kalgutkar, A. S., D. K. Dalvie, N. Castagnoli, Jr., and T. J. Taylor. 2001. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol. 14:1139-1162.
40. Kalgutkar, A. S., R. S. Obach, and T. S. Maurer. 2007. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 8:407-447.
41. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, et al. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
42. Khati, M., M. Schuman, J. Ibrahim, Q. Sattentau, S. Gordon, and W. James. 2003. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J. Virol. 77:12692-12698.
43. Kitanaka, J., N. Kitanaka, T. Tatsuta, and M. Takemura. 2005. 2-Phenylethylamine in combination with l-deprenyl lowers the striatal level of dopamine and prolongs the duration of the stereotypy in mice. Pharmacol. Biochem. Behav. 82:488-494.
44. Koh, Y., H. Nakata, K. Maeda, H. Ogata, G. Bilcer, T. Devasamudram, J. F. Kincaid, P. Boross, Y. F. Wang, Y. Tie, P. Volarath, L. Gaddis, R. W. Harrison, I. T. Weber, A. K. Ghosh, and H. Mitsuya. 2003. Novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
45. Kohler, J. J., and W. Lewis. 2007. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ. Mol. Mutagen. 48:166-172.
46. Kourlas, H., and D. S. Schiller. 2006. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin. Ther. 28:36-44.
47. Lewis, W., and M. C. Dalakas. 1995. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1:417-422.
48. Lewis, W., B. J. Day, and W. C. Copeland. 2003. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2:812-822.
49. Lewis, W., J. F. Simpson, and R. R. Meyer. 1994. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ. Res. 74:344-348.
50. Melroy, J., and V. Nair. 2005. The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Curr. Pharm. Des. 11:3847-3852.
51. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C. K. Shih, K. Eckner, S. Hattox, J. Adams, et al. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
52. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
53. Mocroft, A., M. J. Gill, W. Davidson, and A. N. Phillips. 1998. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 12:2161-2167.
54. Mutimura, E., N. J. Crowther, A. Stewart, and W. Todd Cade. 2008. The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspective. J. Cardiometab. Syndr. 3:106-110.
55. O'Carroll, A. M., M. C. Anderson, I. Tobbia, J. P. Phillips, and K. F. Tipton. 1989. Determination of the absolute concentrations of monoamine oxidase A and B in human tissues. Biochem. Pharmacol. 38:901-905.
56. Patel, J., B. Buddha, S. Dey, D. Pal, and A. K. Mitra. 2004. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther. 11:262-277.
57. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
58. Robbins, B. L., R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42:612-617.
59. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, et al. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
60. Rodriguez, M. J., J. Saura, C. C. Finch, N. Mahy, and E. E. Billett. 2000. Localization of monoamine oxidase A and B in human pancreas, thyroid, and adrenal glands. J. Histochem. Cytochem. 48:147-151.
61. Saura, J., E. Nadal, B. van den Berg, M. Vila, J. A. Bombi, and N. Mahy. 1996. Localization of monoamine oxidases in human peripheral tissues. Life Sci. 59:1341-1349.
62. Sekiguchi, T., and T. Hunter. 1998. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells. Oncogene 16:369-380.
63. Shih, J. C., J. Grimsby, and K. Chen. 1990. The expression of human MAO-A and B genes. J. Neural Transm. Suppl. 32:41-47.
64. Slee, E. A., C. Adrain, and S. J. Martin. 2001. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 276:7320-7326.
65. Thorpe, L. W., K. N. Westlund, L. M. Kochersperger, C. W. Abell, and R. M. Denney. 1987. Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. J. Histochem. Cytochem. 35:23-32.
66. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, et al. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
67. Walker, U. A., and K. Brinkman. 2001. An argument for mitochondrial toxicity in highly active antiretroviral therapy-induced lipoatrophy. AIDS 15:1450-1452.
68. Walker, U. A., and K. Brinkman. 2001. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction? HIV Med. 2:163-165.
69. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
70. Youle, M. 2007. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J. Antimicrob. Chemother. 60:1195-1205.
71. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, et al. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605